Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deuremidevir hydrobromide for RSV infection in infants (Phase III)
CTR20260561Phase 3Active
- Sponsor
- Vigonvita Life Sciences
- Start
- Mar 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of deuremidevir in respiratory syncytial virus disease (RSV), sponsored by Vigonvita Life Sciences. Started Mar 2026; status: active.
02
Drugs
deuremidevir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on CTR20260561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260561.